EP0245368A1 - Treatment of demyelinating diseases - Google Patents

Treatment of demyelinating diseases

Info

Publication number
EP0245368A1
EP0245368A1 EP86906690A EP86906690A EP0245368A1 EP 0245368 A1 EP0245368 A1 EP 0245368A1 EP 86906690 A EP86906690 A EP 86906690A EP 86906690 A EP86906690 A EP 86906690A EP 0245368 A1 EP0245368 A1 EP 0245368A1
Authority
EP
European Patent Office
Prior art keywords
disease
colchicine
treatment
active ingredient
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP86906690A
Other languages
German (de)
French (fr)
Other versions
EP0245368A4 (en
Inventor
Herman J. Weinreb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP0245368A1 publication Critical patent/EP0245368A1/en
Publication of EP0245368A4 publication Critical patent/EP0245368A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Definitions

  • This: invention relates to the treatment of demyelinating diseases f particularly multiple sclerosis (MS), with colchicine or_ colchiceine.
  • MS multiple sclerosis
  • Demyelinating diseases of central or peripheral origin are diseases which destroy myelin which is a substance compounded principally of fats and proteins. It is wrapped in numerous thin layers around nerve fibers where it acts as an insulator and speeds the transmission of messages along the nerve fibers. These afflictions include for example MS, Guillain-Barre syndrome and polymyositis. Of these, MS is by far the most prevalent. This invention will be described principally as it relates to MS.
  • MS is a disease of profound suffering and pervasive disability, the etiology of which remains unknown despite intensive investigation. It consists of patches or plagues of damaged myelin scattered throughout the central nervous system resulting from demyelination and subsequent scar formation.
  • multiple sclerosis describes the fact that in this disease there are many damaged areas filled with sclerotic (scar) .tissue. Over a long period, new scar tissue may develop or old ones enlarge. The result is progressive degeneration of the nervous system resulting in progressive debilitation of the afflicted individual.
  • SL'_ OSTITUTE SHEET MS significantly affects the most productive human age group (20-40 yrs). There are close to a million victims in the United States alone. The chief consequence of the disease is increasing deterioration of neurological function. Most victims are confined to wheelchairs or bed after 10 years. The prevalence ranges from 50/100,000 in the United States to 200/100,000 in Canada, Northern Great Britain, parts of France, Scandinavia and Russia.
  • ACTH has been of some benefit in promoting remission of acute attacks, but has not been shown to modify the overall course of the disease.
  • Combination therapy with ACTH and cyclophosphamide have shown some promise in temporarily halting the progression of severe MS.
  • the work is very recent, and no final conslusion has been possible.
  • Copolymer-I a synthetic polypeptide resembling myelin basic protein has shown some benefit, but these results are also too recent for proper evaluation.
  • Colchicine is (S)-N-(5,6,7,9-tetrahydro-9-oxabenzo [a] heptaten-7-yl) acetamide. It has long been known as a therapeutic agent for humans, particularly as a gout suppressant and in the treatment of Familial Mediterranean Fever. It may be safely administered both orally and parenterally. Its activity in the mammalian body is well known and understood. Colchiceine is the 10- demethylated homolog of colchicine. It has also been used for the same purposes. Colchicine is the preferred therapeutic agent for the known utilities. It is also the preferred agent for use in this invention because it is readily available at reasonable cost and is extremely effective in retarding the progression of MS.
  • colchicine and colchiceine may be administered to humans to treat demyelinating diseases, such as MS by retarding the process of demyelination. It is most convenient to administer the therapeutic agent orally, but parenteral administration including intravenous or intramuscular injection may also be employed.
  • An effective dose for treating the disease will vary with a number of factors well known and understood by the physician. These include, for example, age and weight of the patients and the status of the disease.
  • SHEET may vary from about .02 to .04 mg/kg of body weight per day.
  • the required dosage will be administered once a day in a sustained release doage unit which may contain 1.2 to 2.4 mg of active compound as the principal active ingredient.
  • a sustained release doage unit which may contain 1.2 to 2.4 mg of active compound as the principal active ingredient.
  • Another convenient dosage unit is a scored tablet, each tablet containing 0.2 to 0.4 mg of active agent per scored segment. Such tablets are particularly useful since they permit the physician to investigate a large number of dosage regimens and titrate the optimum effective dosage for an individual patient.
  • the oral and parenteral dosage units will be prepared in accordance with standard procedures and will contain the selected active compound as the only or principal active ingredient in the composition.
  • Any of a wide variety of known inert excipients may be employed to prepare compositions useful in the practice of this invention. These include, for example, dextrose, starch, talc, various types of clay, mineral oil, cottonseed or sesame oil, as well as water or various miscible and immiscible aqueous compositions in which the therapeutic agent is soluble or may be suspended with the aid of known surfactants.
  • the active ingredient can be formulated in tablet form with water soluble binding agents such as lactose or other palatable carbohydrates.
  • SUBSTITUTE SHEET For rectal administration suppositories or inserts containing the active ingredient dispersed in such reagents as cocoa butter, petroleum, or other natural lubricants or in a synthetic emmollient such as polyethylene glycol 1000 or polyethylene glycol 4000 may be used.
  • Transdermal administration will normally be from sustained release preparation which may be applied as a patch or. from a gauze applied to the skin.
  • the preferred method of administering the active agents of this invention is from sustained release dosage forms since this is most convenient for patients, and avoids the necessity of constant clock watching or interruption of normal daily activities.
  • a number of compositions suitable for such preparations are known and can be usefully employed.
  • One convenient procedure is to formulate the selected motility control agent in a time disintegrating tablet or pellet coated with various thicknesses of known materials such as carnauba wax, cellulose esters and ethers, fats, keratin, gluten or various natural or synthetic esters.
  • Tablets in which the motility control agent is ⁇ contained in a slowly dissolving core such as a core of stearic acid or castor oil are useful.
  • Mixed release granule tablets comprising mixtures of the drug itself and the drug in separate particles coated with materials which dissolve at different rates such as dehydrogenated castor oil or fatty acids can also be employed.
  • the active material can be bound to an ion exchange resin such as a sulfuric acid type cation exchange resin.
  • the active agents of this invention are useful in treating the diseases to which this disclosure applies by inhibiting demyelination, thereby abating the progression of neurological disability.
  • MS were treated orally using tablets containing 0.6 mg of colchicine three times per day.
  • Treatment failure was defined as a decline in either the DSS or the Al/UEI by one point or the FSS by two points for a period of one month after beginning colchicine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Méthode de traitement de maladies de démyélinisation telles que la sclérose en plaques par un traitement à base de colchicine ou colchicéine.Method of treatment of demyelination diseases such as multiple sclerosis by a treatment based on colchicine or colchiceine.

Description

TREATMENT OF DEMYELINATING DISEASES
FIELD OF THE INVENTION:
This: invention relates to the treatment of demyelinating diseases f particularly multiple sclerosis (MS), with colchicine or_ colchiceine.
BACKGROUND OF THE INVENTION:
Demyelinating diseases of central or peripheral origin are diseases which destroy myelin which is a substance compounded principally of fats and proteins. It is wrapped in numerous thin layers around nerve fibers where it acts as an insulator and speeds the transmission of messages along the nerve fibers. These afflictions include for example MS, Guillain-Barre syndrome and polymyositis. Of these, MS is by far the most prevalent. This invention will be described principally as it relates to MS.
MS is a disease of profound suffering and pervasive disability, the etiology of which remains unknown despite intensive investigation. It consists of patches or plagues of damaged myelin scattered throughout the central nervous system resulting from demyelination and subsequent scar formation. The name "multiple sclerosis" describes the fact that in this disease there are many damaged areas filled with sclerotic (scar) .tissue. Over a long period, new scar tissue may develop or old ones enlarge. The result is progressive degeneration of the nervous system resulting in progressive debilitation of the afflicted individual.
SL'_ OSTITUTE SHEET MS significantly affects the most productive human age group (20-40 yrs). There are close to a million victims in the United States alone. The chief consequence of the disease is increasing deterioration of neurological function. Most victims are confined to wheelchairs or bed after 10 years. The prevalence ranges from 50/100,000 in the United States to 200/100,000 in Canada, Northern Great Britain, parts of France, Scandinavia and Russia.
In the absence of a known cause for the disease, treatments have= been empirical. The treatments can be divided principally into anti-inflammatory, immunosuppressive, anti-infective and biological response modifications. Additionally, a large number of miscellaneous treatments have been attempted. No satisfactory treatment of MS has yet been revealed.
ACTH has been of some benefit in promoting remission of acute attacks, but has not been shown to modify the overall course of the disease. Combination therapy with ACTH and cyclophosphamide have shown some promise in temporarily halting the progression of severe MS. However, the work is very recent, and no final conslusion has been possible.
Copolymer-I, a synthetic polypeptide resembling myelin basic protein has shown some benefit, but these results are also too recent for proper evaluation.
in 1982 the National Multiple Sclerosis Society published a booklet entitled Therapeutic Claims in Multiple Sclerosis (International Standard Book Number 0-9608098-0-5). In it more than twenty methods of treating MS ranging from diet control to a wide variety of therapeutic agents including, for example, anticoagulants, vasodilators, immunosuppressants, and protease inhibitors are discussed. The majority are characterized as ineffective, not recommended, or not sufficiently tested.
<?? TTUTE SHEET There is a need for a safe, reliable and effective method of treating MS and related diseases so as to retard their progression, particularly a treatment which will retard demyelinating before the disease becomes disabling. It would be especially convenient if treatment could be accomplished by way of sustained release compositions which would decrease the number of separate dosage units required each day during treatment, thus improving compliance.
Colchicine is (S)-N-(5,6,7,9-tetrahydro-9-oxabenzo [a] heptaten-7-yl) acetamide. It has long been known as a therapeutic agent for humans, particularly as a gout suppressant and in the treatment of Familial Mediterranean Fever. It may be safely administered both orally and parenterally. Its activity in the mammalian body is well known and understood. Colchiceine is the 10- demethylated homolog of colchicine. It has also been used for the same purposes. Colchicine is the preferred therapeutic agent for the known utilities. It is also the preferred agent for use in this invention because it is readily available at reasonable cost and is extremely effective in retarding the progression of MS.
THE INVENTION
It has now been discovered that both colchicine and colchiceine may be administered to humans to treat demyelinating diseases, such as MS by retarding the process of demyelination. It is most convenient to administer the therapeutic agent orally, but parenteral administration including intravenous or intramuscular injection may also be employed.
An effective dose for treating the disease will vary with a number of factors well known and understood by the physician. These include, for example, age and weight of the patients and the status of the disease. An effective dose
'._ _i- -_} ΠTUTE SHEET may vary from about .02 to .04 mg/kg of body weight per day.
Most conveniently, the required dosage will be administered once a day in a sustained release doage unit which may contain 1.2 to 2.4 mg of active compound as the principal active ingredient. Another convenient dosage unit is a scored tablet, each tablet containing 0.2 to 0.4 mg of active agent per scored segment. Such tablets are particularly useful since they permit the physician to investigate a large number of dosage regimens and titrate the optimum effective dosage for an individual patient.
It has been observed that dosage regimens appreciably below those suggested above are generally ineffective. Dosages appreciably above these values are not generally recommended for patients using colchicine or colchiceine for any purpose, because of undesirable side reactions, particularly diarrhea.
The oral and parenteral dosage units will be prepared in accordance with standard procedures and will contain the selected active compound as the only or principal active ingredient in the composition. Any of a wide variety of known inert excipients may be employed to prepare compositions useful in the practice of this invention. These include, for example, dextrose, starch, talc, various types of clay, mineral oil, cottonseed or sesame oil, as well as water or various miscible and immiscible aqueous compositions in which the therapeutic agent is soluble or may be suspended with the aid of known surfactants.
For buccal and sublingual administration the active ingredient can be formulated in tablet form with water soluble binding agents such as lactose or other palatable carbohydrates.
SUBSTITUTE SHEET For rectal administration suppositories or inserts containing the active ingredient dispersed in such reagents as cocoa butter, petroleum, or other natural lubricants or in a synthetic emmollient such as polyethylene glycol 1000 or polyethylene glycol 4000 may be used.
Transdermal administration will normally be from sustained release preparation which may be applied as a patch or. from a gauze applied to the skin.
The preferred method of administering the active agents of this invention is from sustained release dosage forms since this is most convenient for patients, and avoids the necessity of constant clock watching or interruption of normal daily activities. A number of compositions suitable for such preparations are known and can be usefully employed.
One convenient procedure is to formulate the selected motility control agent in a time disintegrating tablet or pellet coated with various thicknesses of known materials such as carnauba wax, cellulose esters and ethers, fats, keratin, gluten or various natural or synthetic esters. Tablets in which the motility control agent is^ contained in a slowly dissolving core such as a core of stearic acid or castor oil are useful. Mixed release granule tablets comprising mixtures of the drug itself and the drug in separate particles coated with materials which dissolve at different rates such as dehydrogenated castor oil or fatty acids can also be employed. Alternatively the active material can be bound to an ion exchange resin such as a sulfuric acid type cation exchange resin.
It has been established that the active agents of this invention are useful in treating the diseases to which this disclosure applies by inhibiting demyelination, thereby abating the progression of neurological disability.
SUBSTITUTE SHEET In one such test, 16 MS patients with chronic progressive
MS were treated orally using tablets containing 0.6 mg of colchicine three times per day.
All patients met published criteria for clinically defined MS and had a chronic progressive disease profile at the time of testing in the independent opinion of two neurologists. The instruments for quantitating disease were the Standard neurological Exam (SNE), the Functional Status Scale (FSS), the Disability Status Scale (DSS), the Ambula±±αrr. Index (Al) and the Upper Extremity Index (UEI). The definition of chronic progressive disease, the quantity of progression required, and the inclusion and exclusion criteria followed thestandard, art accepted guidelines. Patients were obtained from a population being followed at The Rockefeller University Hospital (RUH) and from local referring physicians. Patients were hospitalized for up to two weeks at RUH, where baseline studies of their medical and neurologic status were performed, along with baseline laboratory studies including the CBC, ESR, SMA-6, SMA-12, UA, EKG, CXR, and stool guaiac. Lumbar punctures and studies of immune function were also performed.
Neurological assessments during the course of treatment were performed independently by two neurologists. After obtaining informed consent the patients began treatment and were evaluated at appropriate intervals to determine their status. Follow-up evaluation consisted of the history and physical- exam, neurological exam as described by the above criteria and laboratory studies consisting of the CBC, ESR, SMA-6, SMA-12, UA and occult stool blood. Treatment failure was defined as a decline in either the DSS or the Al/UEI by one point or the FSS by two points for a period of one month after beginning colchicine.
The results are shown in the following Table.
«n UE_?»3«?■TITUTE SHEET TABLE
Patient/Age/ Duration of Disability Ambulation Followup Sex Disease(yrs) Status* Index* (mos)
FRCA/41/M- 3 6A 5 12
JOFE/42/M 15 6B 6 10
ALDE/34/M 5 6A 4 9
MAAD/46/F 10 6B 6 9
BAFR/42/F 3 2 2 8
VIKU/32/F 1 2 2 7
SUPE/43/F 9 3 2 7
EPLI/61/M 30 6A 4 6 AJA/35/M 7 6B 6 5
POFA/39/F 20 6B 6 5
JOST/24/F 2 2 2 5
MAJO/45/F 16 7 7 4
ROEH/55/M 23 6A 4 4
JOCA/52/M 25 6A 4 4
HIHE/56/F 1 3 3 4
RIPR/47/M 15 6A 5 4
*As proposed by Weiner et al (NEngl. J. Med 1983;308:173-80)
The integers in the columns under Disability Status and Ambulation Index indicate the status of the disease at the start of the treatment as determined by the Weiner protocol. None of the patients tested showed further progression of the disease beyond their original status for the periods of time listed in the last column.

Claims

Claims
1. A method of treating demyelinating diseases of central or peripheral origin to retard their progression in a patient afflicted with such a disease which comprises administering to such a patient a composition containing as the principal active ingredient an amount of colchicine or colchiceine which is effective to retard the progression of the disease.
2 A method as in claim 1 wherein the active ingredient is colchicine.
3. A method as in claim 2 wherein the disease is multiple sclerosis.
4. A sustained release therapeutic composition containing colchicine or colchiceine as the principal active ingredient.
5. A composition as in claim 1 wherein the active ingredient is colchicine.
πp^TITUTE SHEET
EP19860906690 1985-10-29 1986-10-27 Treatment of demyelinating diseases. Ceased EP0245368A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79261085A 1985-10-29 1985-10-29
US792610 1997-01-31

Publications (2)

Publication Number Publication Date
EP0245368A1 true EP0245368A1 (en) 1987-11-19
EP0245368A4 EP0245368A4 (en) 1988-01-25

Family

ID=25157487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860906690 Ceased EP0245368A4 (en) 1985-10-29 1986-10-27 Treatment of demyelinating diseases.

Country Status (3)

Country Link
EP (1) EP0245368A4 (en)
JP (1) JPS63501154A (en)
WO (1) WO1987002583A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3626306A1 (en) * 1986-08-02 1988-02-11 Behringwerke Ag USE OF 15-DEOXYSPERGUALIN AS A MEDICINAL PRODUCT
EP4338740A1 (en) 2022-09-13 2024-03-20 Johannes Gutenberg-Universität Mainz A transdermal patch for promoting or accelerating myelination and/or remyelination

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 106, No. 5, 2nd February 1987, page 30, Abstract No. 27521q, Columbus, Ohio, US; M.J. LYONS et al.: "Inhibition of acute experimental allergic encephalomyelitis in mice by colchicine", & J. Exp. Med. 1986, 164(5), 1803-8, Abstract. *
CHEMICAL ABSTRACTS, Vol. 90, No. 23, 4th June 1979, page 436, Abstract No. 184235t, Columbus, Ohio, US; D.F. HORROBIN: "Multiple sclerosis: the rational basis for treatment with colchicine and evening primrose oil", & Med. Hypotheses, 1979, 5(3), 365-78, Abstract. *
CHEMICAL ABSTRACTS, Vol. 93, No. 26, 29th December 1980, page 382, Abstract No. 245390a, Columbus, Ohio, US; M. YOSHIDA: "Studies on entrapping of enzymes and drugs in matrixes by radiation-induced polymerization at low temperatures and their capabilities", & Nippon Genshiryoku Kenkyusho, (Rep.) Jaeri-M 1980, Jaeri-M-8766, Abstract. *
See also references of WO8702583A1 *

Also Published As

Publication number Publication date
EP0245368A4 (en) 1988-01-25
JPS63501154A (en) 1988-04-28
WO1987002583A1 (en) 1987-05-07

Similar Documents

Publication Publication Date Title
Clemmensen et al. Thalidomide neurotoxicity
Rowbotham et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia
Cole Therapeutic efficacy of antidepressant drugs: a review
Yahr et al. Treatment of parkinsonism with levodopa
Guerrini et al. Cortical myoclonus in Angelman syndrome
WARD 1986 Volvo Award in Clinical Sciences: tricyclic antidepressants for chronic low-back pain: mechanisms of action and predictors of response
Kasperek et al. Stiff-man syndrome and encephalomyelitis: report of a case
US5679715A (en) Method for treating multiple sclerosis
Paterson et al. Drug therapy of glaucoma.
LOCKIE et al. Treatment of two reactions due to gold: Response of thrombopenic purpura and granulocytopenia to BAL therapy
Robberecht et al. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction
Fryda-Kaurimsky et al. Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam
ZIEGLER Acute disseminated encephalitis: Some therapeutic and diagnostic considerations
US4760092A (en) Treatment of demyelinating diseases
Norris et al. Trial of baclofen in amyotrophic lateral sclerosis
Korwin‐Piotrowska et al. Experience of Padma 28 in multiple sclerosis
Estape et al. Ketorolac, a new non-opioid analgesic: a double-blind trial versus pentazocine in cancer pain
US4331145A (en) Multiple sclerosis treatment
Alim et al. Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: a test of the cocaine-agonist hypothesis
Tompsett XIV Relation of Dosage to Streptomycin Toxicity
EP0245368A1 (en) Treatment of demyelinating diseases
Montastruc et al. Parkinson's disease and hypertension: chronic bromocriptine treatment
Shelton et al. Simulated abuse of tybamate in man: Failure to demonstrate withdrawal reactions
Pappas et al. Neonatal systemic 6-hydroxydopamine and dorsal tegmental bundle lesion: comparison of effects on CNS norepinephrine and the postdecapitation reflex
Awadzi et al. The chemotherapy of onchocerciasis IX: The effect of prednisone plus cyproheptadine on the Mazzotti reaction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870721

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19880125

17Q First examination report despatched

Effective date: 19890824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19910714